Who is sponsoring NCT04275687?

NCT04275687 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04275687?

Interventions in NCT04275687: thoracic irradiation, Concurrent chemotherapy.

What condition does NCT04275687 study?

NCT04275687 studies Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy.

Is NCT04275687 still recruiting?

NCT04275687 is currently status unknown. Last updated 21 February 2020.

Last reviewed 2020-02-21 · How we verify

NCT04275687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer

Status unknown Phase 2 Last updated 21 February 2020

What this trial tests

Phase 2 trial testing thoracic irradiation in Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy in 35 participants. Status unknown.

Timeline

1 March 2020

Primary endpoint
1 February 2025

1 February 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	1 March 2020
Primary completion	1 February 2025
Estimated completion	1 February 2025
Sites	1 location across China

Drugs / interventions tested

thoracic irradiation
Concurrent chemotherapy — full drug profile →

Conditions studied

Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy — all drugs for Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective phase II study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04275687 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 21 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04275687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing